Lancet study a sham?
This article was originally published in The Tan Sheet
Executive Summary
Editors of The Lancet issued an "expression of concern" Jan. 17 about a study published in the journal in October which appeared to be based on "complete fabrication" by the study's lead author. John Sudbo, MD, PhD, Norwegian Radium Hospital, et al., found in a study that long-term use of NSAIDs was linked to reduced incidence of oral cancer but increased risk of death from cardiovascular disease. The hospital alerted Lancet editors to the problem Jan. 13, and the publication states that "the journal has not yet received written confirmation...that fabrication actually took place." The hospital has appointed an investigation committee to look into the matter. Sudbo's findings were first presented at the American Association for Cancer Research annual meeting in April (1"The Tan Sheet" April 25, 2005, p. 10)...
You may also be interested in...
False Lancet study
The Lancet has "received confirmation" that a study published by the journal in October on NSAIDs and reduction of oral cancer contains fabricated data, the publication announces Feb. 4. The false data was provided by lead author John Sudbo, MD/PhD, Norwegian Radium Hospital. The journal's editors released an "expression of concern" about the fabricated data Jan. 17 when they were first alerted to the problem (1"The Tan Sheet" Jan. 23, 2005, In Brief)...
NSAID Use Long-Term May Increase Cardiovascular Death Risk – Study
A small study showing that smokers using NSAIDs are twice as likely to die from cardiovascular causes as smokers who do not use NSAIDs represents another blow to the safety profile of the drug class
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.